Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00247702
Status:
UNKNOWN
Last Update Posted:
2005-11-02
First Post:
2005-11-01
Brief Title:
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Study of the Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
Status:
UNKNOWN
Status Verified Date:
2005-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Oral warfarin anticogulation for the prevention and treatment of patients with venous thromboembolism is one of the most used therapies in clinical practice Patients require different dosage to achieve the target therapeutic anticoagulation Optimal dosage and bleeding complication are two most clinical concerns Besides of multiple individual factors eg age dietary intake vitamin supplement drug compliance etc some genetic factors may determine the drug requirement and safety
The cytochrome P450 CYP2C9 is a liver enzyme required for the oxidative metabolism of warfarin The vitamin K epoxide redutase VKOR is a liver enzyme associated with the reuse of the oxidative hydroquinone form of vitamin K The VKOR enzyme is the target of warfarin Recent studies revealed both genes may determine the pharmacodynamic of warfarin anticogualation To date there are more than thirteen identified polymorphism at CYP2C9 gene Majority of those variant polymorphisms may decrease the warfarin requirement The VKOR complex subunit 1 VKORC1 is a newly identified gene Some polymorphisms also were reported
As we know the Chinese patients need a lower dosage of warfarin in comparison with the Caucasian patients We are interested in finding the genetic causes of Taiwneses Chinese patients In our study we will first identify the polymorphism patterns of these two genes in normal population Then we will try to find the association between these polymorphism and patient warfarin requirement Our pharmacogenetics study will be valuable for prevention of bleeding complication of warfarin treatment in Chinese population
The cytochrome P450 CYP2C9 is a liver enzyme required for the oxidative metabolism of warfarin The vitamin K epoxide redutase VKOR is a liver enzyme associated with the reuse of the oxidative hydroquinone form of vitamin K The VKOR enzyme is the target of warfarin Recent studies revealed both genes may determine the pharmacodynamic of warfarin anticogualation To date there are more than thirteen identified polymorphism at CYP2C9 gene Majority of those variant polymorphisms may decrease the warfarin requirement The VKOR complex subunit 1 VKORC1 is a newly identified gene Some polymorphisms also were reported
As we know the Chinese patients need a lower dosage of warfarin in comparison with the Caucasian patients We are interested in finding the genetic causes of Taiwneses Chinese patients In our study we will first identify the polymorphism patterns of these two genes in normal population Then we will try to find the association between these polymorphism and patient warfarin requirement Our pharmacogenetics study will be valuable for prevention of bleeding complication of warfarin treatment in Chinese population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None